Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience

Por Schrama, J G, Holtkamp, M J, Baars, J W, Schornagel, J H, Rodenhuis, S
Publicado em 2003

Evaluating the quality of life of cancer patients: assessments by patients, significant others, physicians and nurses

Por Sneeuw, K C A, Aaronson, N K, Sprangers, M A G, Detmar, S B, Wever, L D V, Schornagel, J H
Publicado em 1999

Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.

Por van der Wall, E., Rutgers, E. J., Holtkamp, M. J., Baars, J. W., Schornagel, J. H., Peterse, J. L., Beijnen, J. H., Rodenhuis, S.
Publicado em 1996

Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients

Por Joerger, M, Huitema, A D R, van den Bongard, H J G D, Baas, P, Schornagel, J H, Schellens, J H M, Beijnen, J H
Publicado em 2006

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer

Por Helgason, H H, Kruijtzer, C M F, Huitema, A D R, Marcus, S G, ten Bokkel Huinink, W W, Schot, M E, Schornagel, J H, Beijnen, J H, Schellens, J H M
Publicado em 2006